Drug intelligence / Profile preview

MRB

Development stage: Unknown
Lead developer: NAOS Institute of Life Science
Modality: Small Molecules
Administration: Topical

Overview

MRB is a cosmetic active ingredient developed by NAOS Institute of Life Science. It is being investigated for its effectiveness in treating early clinical markers of photoinduced cutaneous aging, specifically actinic lentigo and actinic keratosis. The drug is formulated as a 0.3% serum for topical application. Its proposed mechanism of action involves antioxidant activity and a chaperone effect that fights protein carbonylation, acting on the oxidative stress pathway and maintaining cellular proteostasis.

Beyond the preview

Go deeper on MRB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRB.

Explore the full profile